Receptor News and Research

RSS

Promising drug candidate for chronic intractable itch

If you have an itch, you have to scratch it. But that’s a problem for people with a condition called “chronic intractable itch,” where that itchy sensation never goes away—a difficult-to-treat condition closely associated with dialysis and renal failure.

28 Sep 2015

Genetic test identifies breast cancer patients that can avoid chemotherapy and remain relapse-free following five years of hormone therapy

Genomic Health has announced the presentation of the first results1 from the Trial Assigning IndividuaLised Options for Treatment (Rx), or TAILORx, a large, prospectively conducted trial designed and conducted by the ECOG-ACRIN Cancer Research Group under the sponsorship of the U.S. National Cancer Institute (NCI).

28 Sep 2015

Teva presents new Reslizumab data at European Respiratory Society (ERS) International Congress 2015

Teva Pharmaceutical Industries Ltd., has presented results from a post hoc analysis of two pivotal Phase III clinical trials showing that treatment with reslizumab reduced clinical asthma exacerbations (CAEs) by 75 percent versus placebo in a subgroup of patients with late onset asthma (diagnosed at 40 years of age and older) with elevated blood eosinophils, who were inadequately controlled on inhaled corticosteroids (ICS).

28 Sep 2015

Kolltan announces presentation of data from KTN0158 preclinical study in mast cell tumors at ESMO 2015

Kolltan Pharmaceuticals, Inc. today announced the presentation of data from a preclinical study evaluating KTN0158 in dogs with spontaneous mast cell tumors. KTN0158 is a proprietary, humanized anti-KIT IgG1 monoclonal antibody drug candidate being developed as a potential therapy for cancer and mast cell-related diseases.

28 Sep 2015

Multigene test performed on tumor can identify breast cancer patients who can safely avoid chemotherapy

A major study published in the New England Journal of Medicine is providing the best evidence to date that a 21-gene test done on the tumor can identify breast cancer patients who can safely avoid chemotherapy.

28 Sep 2015

Nivolumab drug improves survival for non-SQ NSCLC patients

Patients with a type of lung cancer called non-squamous non-small cell lung cancer (non-SQ NSCLC) have limited treatment options and a dismal prognosis once their disease has advanced and initial treatment with platinum-based chemotherapy has failed. Second-line treatment is usually with another chemotherapy drug, such as docetaxel or pemetrexed.

28 Sep 2015

Hormonal therapy may protect women's ovaries, increase chances of pregnancy after breast cancer treatment

Young women undergoing chemotherapy for breast cancer may be more likely to remain fertile if they also receive hormonal treatment, according to new research presented to the 2015 European Cancer Congress on Monday and published simultaneously in Annals of Oncology.

28 Sep 2015

Common IBD therapeutic target may protect against intestinal inflammation

Investigators at Children's Hospital Los Angeles have found that a common therapeutic target for the treatment of inflammatory bowel disease (IBD) may actually protect against intestinal inflammation by inhibiting pathogenic T-cells. This discovery, reported in the October 2015 issue of Gastroenterology, could lead to new treatment options for the 65 percent of individuals with IBD who do not respond or become resistant to anti-TNF medications.

26 Sep 2015

Patients with advanced kidney cancer benefit from cabozantinib treatment

Patients with advanced kidney cancer live for nearly twice as long without their disease progressing if they are treated with cabozantinib, a drug that inhibits the action of tyrosine kinases - enzymes that function as an "on" or "off" switch in many cellular processes, including cancer.

26 Sep 2015

H7N9 influenza vaccine failure may be due to immune camouflage, study reveals

The avian influenza A (H7N9) virus has been a major concern since the first outbreak in China in 2013. Due to its high rate of lethality and pandemic potential, H7N9 vaccine development has become a priority for public health officials. However, candidate vaccines have failed to elicit the strong immune responses necessary to protect from infection.

25 Sep 2015

Scientists trace out intricate molecular pathway that may explain tamoxifen resistance in breast cancer patients

For reasons unknown, many patients with breast cancer treated with the estrogen receptor-blocking drug tamoxifen eventually become resistant to the treatment despite the fact that their cancer cells still have the estrogen receptor proteins that the drug normally targets.

24 Sep 2015

Study explores effectiveness of frontline treatments for couples with unexplained infertility

A breast cancer drug with promise for improving the chance that couples with unexplained infertility can have a baby without increasing their risk of multiple births apparently does not deliver, according to a comparative study.

24 Sep 2015

Soft palate plays key role in viruses' ability to spread

Flu viruses come in many strains, and some are better equipped than others to spread from person to person. Scientists have now discovered that the soft palate -- the soft tissue at the back of the roof of the mouth -- plays a key role in viruses' ability to travel through the air from one person to another.

24 Sep 2015

TSRI study reveals key morphine regulator that may help develop less-addictive pain medications

Once used in the 18th century as currency to reverse the trade imbalance between China and Britain, opiates that contain morphine have been misunderstood almost continually ever since.

23 Sep 2015

UCI scientists find potential biomarker for diagnosing certain forms of autism

By identifying a key signaling defect within a specific membrane structure in all cells, University of California, Irvine researchers believe, they have found both a possible reliable biomarker for diagnosing certain forms of autism and a potential therapeutic target.

22 Sep 2015

Palatin Technologies reports net loss of $12.1 million for fourth quarter 2015

Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its fourth quarter and fiscal year ended June 30, 2015.

21 Sep 2015

BGB324 shows enhanced tumour clearance in mouse carcinoma models

BerGenBio AS, an oncology biopharmaceutical company, has announced new preclinical data on lead compound, BGB324, in combination with immune checkpoint inhibitors, has been presented as a poster at CRI-CIMT-EATI-AACR - The Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival, in New York.

21 Sep 2015

New study highlights gap in scientific knowledge about some diabetes drugs

A gap in scientific knowledge about a family of drugs that are used to treat Type 2 diabetes has been highlighted in a new study.

21 Sep 2015

Discovery may lead to potential treatment strategies for type 2 diabetes

Insensitivity to insulin, also called insulin resistance, is associated with type 2 diabetes and affects several cell types and organs in the body. Now, scientists from Sweden's Karolinska Institutet have discovered a mechanism that explains how insulin-producing cells can be insulin resistant and insulin sensitive at the same time.

18 Sep 2015

Manchester researchers reveal why ER+ breast cancer women develop resistance to hormone therapy

University of Manchester researchers funded by Breast Cancer Now have discovered a new explanation as to why women with oestrogen receptor positive (ER+) breast cancer develop resistance to hormone treatment, and a potential new approach to overcome the problem.

18 Sep 2015

Receptor News and Research

Promising drug candidate for chronic intractable itch

Genetic test identifies breast cancer patients that can avoid chemotherapy and remain relapse-free following five years of hormone therapy

Teva presents new Reslizumab data at European Respiratory Society (ERS) International Congress 2015

Kolltan announces presentation of data from KTN0158 preclinical study in mast cell tumors at ESMO 2015

Multigene test performed on tumor can identify breast cancer patients who can safely avoid chemotherapy

Nivolumab drug improves survival for non-SQ NSCLC patients

Hormonal therapy may protect women's ovaries, increase chances of pregnancy after breast cancer treatment

Common IBD therapeutic target may protect against intestinal inflammation

Patients with advanced kidney cancer benefit from cabozantinib treatment

H7N9 influenza vaccine failure may be due to immune camouflage, study reveals

Scientists trace out intricate molecular pathway that may explain tamoxifen resistance in breast cancer patients

Study explores effectiveness of frontline treatments for couples with unexplained infertility

Soft palate plays key role in viruses' ability to spread

TSRI study reveals key morphine regulator that may help develop less-addictive pain medications

UCI scientists find potential biomarker for diagnosing certain forms of autism

Palatin Technologies reports net loss of $12.1 million for fourth quarter 2015

BGB324 shows enhanced tumour clearance in mouse carcinoma models

New study highlights gap in scientific knowledge about some diabetes drugs

Discovery may lead to potential treatment strategies for type 2 diabetes

Manchester researchers reveal why ER+ breast cancer women develop resistance to hormone therapy

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News